Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status

Clinical trial NCT03519412 · COMPLETED

Trial details

NCT number: NCT03519412
Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Neoplasms Microsatellite Instability

Start date: 2019-01-23
Primary completion: 2025-01-08
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.